Also known as: PTCL
A phase 3 trial of azacitidine and chidamide plus CHOP in untreated PTCL showed a significant overall survival improvement but no significant gains in response rate or progression-free survival. The study suggests molecular profiling could guide future therapies.
The global oncology market is projected to grow from $280 billion in 2026 to $748 billion by 2035 at 11.54% CAGR, driven by rising cancer incidence, precision medicine expansion, and strong immunotherapy pipelines across multiple tumor types.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07750886 |
Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) |
RECRUITING | |
| NCT07746245 |
The Efficacy of CAPCT in Patients With PTCL |
NOT_YET_RECRUITING | PHASE2 |
| NCT07730515 |
Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma |
RECRUITING | PHASE1/PHASE2 |
| NCT07234162 |
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) |
RECRUITING | PHASE3 |
| NCT07055477 |
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) |
RECRUITING | PHASE1 |
| NCT06176690 |
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas |
RECRUITING | PHASE1 |
| NCT02232516 |
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma |
COMPLETED | PHASE2 |
